×
About 1,963 results

ALLMedicine™ Burkitt Lymphoma Center

Research & Reviews  733 results

A novel prognostic index for sporadic Burkitt lymphoma in adult patients: a real-word m...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740497
BMC Cancer; Chen MT, Pan F et. al.

Jan 9th, 2022 - Adult sporadic Burkitt lymphoma (BL) is a rare but highly aggressive subtype of lymphoma which lacks its own unique prognostic model. Systemic inflammatory biomarkers have been confirmed as prognostic markers in several types of malignancy. Our ob...

Primary chest wall Burkitt lymphoma in a case of HIV infection with immune reconstitution.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719129
BMJ Case Reports; Jain A, Arun VA et. al.

Jan 1st, 2022 - Burkitt lymphoma (BL) develops at an increased frequency in patients with HIV irrespective of the CD4 count. Lymph nodes and gastrointestinal tract are common sites of involvement by BL; however, primary chest wall BL is rare. A 52-year-old man on...

Clinical presentation of gastric Burkitt lymphoma presenting with paraplegia and acute ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661376
World Journal of Gastroenterology; Lin Y, Pan YH et. al.

Dec 30th, 2021 - The incidence of gastric Burkitt lymphoma (BL), presenting as paraplegia and acute pancreatitis, is extremely low. BL is a great masquerader that presents in varied forms and in atypical locations, and it is prone to misdiagnosis and missed diagno...

The danger molecule HMGB1 cooperates with the NLRP3 inflammasome to sustain expression ...
https://doi.org/10.1016/j.virol.2021.12.002
Virology Reinhart NM, Akinyemi IA et. al.

Dec 19th, 2021 - High mobility group box 1 (HMGB1) is an important chromatin protein and a pro-inflammatory molecule. Though shown to enhance target DNA binding by the Epstein-Barr virus (EBV) lytic switch protein ZEBRA, whether HMGB1 actually contributes to gamma...

The development of an international childhood cancer hospital register database in 13 A...
https://doi.org/10.1002/pbc.29464
Pediatric Blood & Cancer; Mallon B, Kaboré R et. al.

Dec 17th, 2021 - The establishment of an international hospital-based register (HBR) for the French African Pediatric Oncology Group (GFAOP) was a necessary step in the group's clinical research program. With help from the Sanofi Espoir Foundation's "My Child Matt...

see more →

Guidelines  2 results

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Gu...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline.
https://doi.org/10.1016/j.clon.2016.09.004
Clinical Oncology (Royal College of Radiologists (Great B... Prica A, Baldassarre F et. al.

Oct 18th, 2016 - Rituximab is the first monoclonal antibody to be approved for use by the US Food and Drug Administration in cancer. Its role in the treatment of non-Hodgkin lymphoma, including chronic lymphocytic leukaemia (CLL), has evolved significantly. We aim...

see more →

Clinicaltrials.gov  9 results

Phase I Trial of PCLX-001 in B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies
https://clinicaltrials.gov/ct2/show/NCT04836195

Dec 3rd, 2021 - This is a phase I dose-escalation study of oral PCLX-001, conducted in a multicenter, non-randomized, open-label, non-controlled design. The study is comprised of two parts: Part A (single-agent dose escalation) and Part B (single-agent expansion ...

DLBCL Treatment in Children and Adolescents
https://clinicaltrials.gov/ct2/show/NCT04726995

Jan 27th, 2021 - Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma that accounts for approximately 10%-20% of pediatric and adolescent non-Hodgkin's lymphomas (NHLs). The incidence increases with age, with 37% of NHLs patients being adolescents aged....

A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed
https://clinicaltrials.gov/ct2/show/NCT03128164

Nov 18th, 2019 - Both Stage I and Stage II include the following periods: screening period, treatment period, safety follow-up period, and extended progression free survival (PFS) follow-up period, as defined in Dose Escalation Stage (Stage I). Dose escalation wil...

A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas
https://clinicaltrials.gov/ct2/show/NCT02700022

Nov 20th, 2017 - This phase I/Ib study is designed to establish the safety and maximum tolerated dose (MTD, which will also be the recommended phase II dose (RP2D)) of the aurora kinase A inhibitor alisertib when combined with dose-adjusted (DA)-R-EPOCH (rituximab...

A Safety Study of SGN-CD19A for Leukemia and Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01786096

Jul 2nd, 2017 - This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in adult and pediatric patients with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL), Burkitt lymphoma or ...

see more →

News  41 results

FDA Approves Rituximab for Multiple Pediatric Cancers
https://www.medscape.com/viewarticle/964124

Dec 3rd, 2021 - The US Food and Drug Administration yesterday approved rituximab (Rituxan) in combination with chemotherapy for pediatric patients (age 6 months to <18 years) with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (...

Devimistat Granted Orphan Drug Designation in Europe for Relapsed/Refractory Burkitt Lymphoma
https://www.onclive.com/view/devimistat-granted-orphan-drug-designation-in-europe-for-relapsed-refractory-burkitt-lymphoma

Nov 23rd, 2021 - The European Medicines Agency has granted an orphan drug designation to devimistat (CPI-613), a novel compound targeting mitochondria, for the treatment of patients with relapsed or refractory Burkitt lymphoma.1 The intravenous lipoate analog was...

Polatuzumab Vedotin Plus R-CHP Significantly Improves PFS Over R-CHOP in DLBCL
https://www.onclive.com/view/polatuzumab-vedotin-plus-r-chp-significantly-improves-pfs-over-r-chop-in-dlbcl

Aug 10th, 2021 - Polatuzumab vedotin-piiq (Polivy) in combination with rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) resulted in a statistically significant and clinically meaningful improvement in progression-free survival (PFS) vs ri...

Loncastuximab Tesirine Showcases Substantial Antitumor Activity in Heavily Pretreated Relapsed/Refractory DLBCL
https://www.onclive.com/view/loncastuximab-tesirine-showcases-substantial-antitumor-activity-in-heavily-pretreated-relapsed-refractory-dlbcl

May 18th, 2021 - Loncastuximab tesirine-lypl (Zynlonta) has demonstrated significant antitumor activity with durable responses and an acceptable toxicity profile, when used as a monotherapy in heavily pretreated patients with relapsed or refractory diffuse large B...

Treating High-Grade Lymphoma
https://www.onclive.com/view/treating-high-grade-lymphoma

Apr 2nd, 2021 - Transcript:Krishna V. Komanduri, MD: Leo, you alluded to the fact that we think we know a lot about a double-hit group, but we don’t really know what to do about it. But I think it’s worth talking about now despite those limitations. There are peo...

see more →